X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-11-18 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.36 | +103,612 | 3,152,991 | +3% | +$244,231 | |||||
2026-11-18 | SLS | Sellas Life Sciences Group, Inc. | Burns John Thomas | CFO | S - Sale | $19.18 | -3,831 | 558,893 | -1% | -$73,471 | ||||||
2026-11-18 | SLS | Sellas Life Sciences Group, Inc. | Cicic Dragan | SVP, Chief Development Officer | S - Sale | $19.18 | -6,933 | 557,361 | -1% | -$132,961 | ||||||
2026-11-18 | SLS | Sellas Life Sciences Group, Inc. | Stergiou Angelos M. | Pres, CEO | S - Sale | $19.18 | -26,606 | 1,734,896 | -2% | -$510,250 | ||||||
| M | 2026-11-19 | LPCN | Lipocine Inc. | Higuchi John W. | Dir | P - Purchase | $1.50 | +150,000 | 391,365 | +62% | +$225,225 | |||||
2026-11-20 | AEON | Aeon Biopharma, Inc. | Wilson Alexander Blair | CLO, CSO, Corp Secretary | P - Purchase | $0.13 | +135,706 | 2,318,711 | +6% | +$17,479 | ||||||
2026-11-19 | AEON | Aeon Biopharma, Inc. | Sy Jennifer | Chief Accounting Officer | P - Purchase | $0.13 | +153,846 | 1,655,022 | +10% | +$19,985 | ||||||
2026-11-19 | AEON | Aeon Biopharma, Inc. | Bancroft Robert E. | Pres, CEO | P - Purchase | $0.13 | +152,333 | 3,329,436 | +5% | +$19,590 | ||||||
2026-11-19 | CRMD | Cormedix Inc. | Blum Susan | CFO | P - Purchase | $4.58 | +5,000 | 129,315 | +4% | +$22,900 | ||||||
2026-11-18 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $2.18 | -2,216 | 1,457,596 | 0% | -$4,826 | ||||||
2026-11-18 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $2.18 | -677 | 540,336 | 0% | -$1,475 | ||||||
| D | 2026-11-20 | ORKA | Oruka Therapeutics, Inc. | Quinlan Paul T | GC | S - Sale+OE | $94.89 | -9,000 | 29,995 | -23% | -$853,986 | |||||
| M | 2026-11-18 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $77.86 | -54,980 | 5,037,460 | -1% | -$4,280,760 | |||||
| D | 2026-11-19 | INSM | Insmed Inc | Schaeffer Orlov S Nicole | Chief People Strategy Officer | S - Sale+OE | $145.26 | -101,100 | 41,895 | -71% | -$14,685,602 | |||||
| D | 2026-11-18 | RYTM | Rhythm Pharmaceuticals, Inc. | Shulman Joseph | Chief Technical Officer | S - Sale+OE | $119.91 | -45,921 | 10,461 | -81% | -$5,506,153 | |||||
2026-11-18 | BBOT | Bridgebio Oncology Therapeutics, Inc. | Beltran Pedro | Pres, CEO | S - Sale | $1.84 | -1,870 | 41,659 | -4% | -$3,443 | ||||||
2026-11-17 | LEGN | Legend Biotech Corp | Zhang Ingrid | CEO | P - Purchase | $8.16 | +20,000 | 1,151,860 | +2% | +$163,200 | ||||||
2026-11-19 | DARE | Dare Bioscience, Inc. | Rastetter William H | Dir | S - Sale | $0.45 | -859 | 0 | -100% | -$382 | ||||||
2026-11-19 | ANNX | Annexon, Inc. | Carson William H. | Dir | P - Purchase | $3.58 | +34,000 | 112,405 | +43% | +$121,720 | ||||||
2026-11-18 | CRMD | Cormedix Inc. | Lefkowitz Steven W | Dir | P - Purchase | $4.53 | +11,500 | 169,603 | +7% | +$52,095 | ||||||
2026-11-18 | IMMX | Immix Biopharma, Inc. | Rachman Ilya M | CEO, COB | P - Purchase | $7.10 | +1,408 | 1,143,091 | 0% | +$10,000 | ||||||
2026-11-18 | IMMX | Immix Biopharma, Inc. | Morris Gabriel S | CFO, Pres | P - Purchase | $7.06 | +1,418 | 743,832 | 0% | +$10,011 | ||||||
2026-11-18 | NMAD | Nomad Power Solutions, Inc. | Holloway Michael Andrew | Dir | P - Purchase | $2.82 | +15,000 | 55,000 | +38% | +$42,300 | ||||||
2026-11-18 | FLNA | Filana Therapeutics, Inc. | Anderson Robert Eugene Jr | Dir | P - Purchase | $0.52 | +19,000 | 27,600 | +221% | +$9,880 | ||||||
2026-11-18 | FLNA | Filana Therapeutics, Inc. | Barry Richard | Pres, CEO | P - Purchase | $0.52 | +44,851 | 1,955,947 | +2% | +$23,323 | ||||||
| DM | 2026-11-17 | AVIR | Atea Pharmaceuticals, Inc. | Lucidi Bruno | Dir | S - Sale+OE | $3.96 | -29,360 | 187,990 | -14% | -$116,410 | |||||
2026-11-19 | AVIR | Atea Pharmaceuticals, Inc. | Polsky Bruce | Dir | S - Sale | $4.03 | -8,750 | 149,830 | -6% | -$35,298 | ||||||
2026-11-18 | CRVO | Cervomed Inc. | Alam John J | CEO, Pres, 10% | P - Purchase | $1.53 | +100,000 | 1,596,578 | +7% | +$152,621 | ||||||
2026-11-17 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $35.85 | -429 | 54,226 | -1% | -$15,380 | ||||||
2026-11-17 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $35.85 | -192 | 9,378 | -2% | -$6,883 | ||||||
| D | 2026-11-19 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $565.09 | -8,300 | 45,172 | -16% | -$4,690,229 | |||||
2026-11-19 | KURA | Kura Oncology, Inc. | Powl Brian T. | Chief Commercial Officer | S - Sale | $7.27 | -448 | 112,817 | 0% | -$3,257 | ||||||
2026-11-17 | TNGX | Tango Therapeutics, Inc. | Ketchum John B | Dir | S - Sale | $24.08 | -3,333 | 21,604 | -13% | -$80,259 | ||||||
2026-11-18 | BMRN | Biomarin Pharmaceutical Inc | Friberg Gregory R | EVP, Chief R, D Officer | S - Sale | $58.81 | -5,147 | 42,585 | -11% | -$302,711 | ||||||
| M | 2026-11-17 | FBIO | Fortress Biotech, Inc. | Rosenwald Lindsay A Md | Pres, CEO, COB, 10% | P - Purchase | $1.85 | +136,723 | 4,723,564 | +3% | +$252,583 | |||||
| M | 2026-11-17 | FBIO | Fortress Biotech, Inc. | Jin David | CFO | P - Purchase | $1.84 | +47,605 | 1,700,366 | +3% | +$87,814 | |||||
| D | 2026-11-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | CHIEF MEDICAL OFFICER | S - Sale+OE | $46.84 | -5,000 | 25,000 | -17% | -$234,203 | |||||
2026-11-18 | NMAD | Nomad Power Solutions, Inc. | Travaglini John Francis | Dir | P - Purchase | $2.85 | +5,000 | 5,000 | New | +$14,270 | ||||||
2026-11-17 | ACRV | Acrivon Therapeutics, Inc. | Peterson Katharine | Chief Accounting Officer | S - Sale | $1.45 | -107 | 17,926 | -1% | -$155 | ||||||
| D | 2026-11-17 | AVLN | Avalyn Pharma Inc. | Lazarus Howard | Chief Medical Officer | S - Sale+OE | $27.90 | -13,300 | 0 | -100% | -$371,027 | |||||
2026-11-17 | ACRV | Acrivon Therapeutics, Inc. | Miller Mary | GC | S - Sale | $1.45 | -193 | 81,009 | 0% | -$280 | ||||||
| D | 2026-11-18 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $578.83 | -5,410 | 668,728 | -1% | -$3,131,476 | |||||
2026-11-17 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Officer | S - Sale | $1.45 | -416 | 52,176 | -1% | -$603 | ||||||
2026-11-17 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | S - Sale | $1.45 | -628 | 145,721 | 0% | -$911 | ||||||
2026-11-17 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO | S - Sale | $1.45 | -1,780 | 2,614,131 | 0% | -$2,581 | ||||||
2026-11-19 | ZOMDF | Zomedica Corp. | Powers Johnny D | Dir | P - Purchase | $0.08 | +175,000 | 4,600,000 | +4% | +$14,525 | ||||||
| M | 2026-11-17 | NBP | Novabridge Biosciences | Hagler Mark Arnold | Chief Commercial Officer | P - Purchase | $0.37 | +230,000 | 460,000 | +100% | +$85,882 | |||||
2026-11-17 | KROS | Keros Therapeutics, Inc. | Newton Charles W. | Dir | S - Sale | $10.85 | -551 | 11,563 | -5% | -$5,981 | ||||||
2026-11-17 | KROS | Keros Therapeutics, Inc. | Prener Anne | Dir | S - Sale | $10.83 | -575 | 12,637 | -4% | -$6,230 | ||||||
| DM | 2026-11-17 | AVLN | Avalyn Pharma Inc. | Baranowski Lyn | CEO | S - Sale+OE | $27.84 | -52,500 | 0 | -100% | -$1,461,457 | |||||
| D | 2026-11-17 | AVLN | Avalyn Pharma Inc. | Rhodes Melissa | COO | S - Sale+OE | $27.90 | -13,300 | 0 | -100% | -$371,046 | |||||
| D | 2026-11-17 | AVLN | Avalyn Pharma Inc. | Carlson Douglas R | See Remarks | S - Sale+OE | $27.90 | -14,875 | 0 | -100% | -$414,983 | |||||
2026-11-17 | FLNA | Filana Therapeutics, Inc. | Barry Richard | Pres, CEO | P - Purchase | $0.48 | +132,926 | 1,911,096 | +7% | +$63,804 | ||||||
| M | 2026-11-17 | CVSI | Cv Sciences, Inc. | Cheever Charlie E III | 10% | P - Purchase | $0.01 | +2,030,711 | 34,120,348 | +6% | +$20,307 | |||||
2026-11-17 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.09 | +50,000 | 1,743,000 | +3% | +$404,680 | ||||||
2026-11-18 | CLNN | Clene Inc. | Wilcox Reed N | Dir | P - Purchase | $3.42 | +10,000 | 38,756 | +35% | +$34,240 | ||||||
2026-11-18 | CATX | Perspective Therapeutics, Inc. | Williamson Robert F III | Dir | P - Purchase | $0.80 | +15,000 | 183,744 | +9% | +$12,000 | ||||||
| DM | 2026-11-16 | AVIR | Atea Pharmaceuticals, Inc. | Polsky Bruce | Dir | S - Sale+OE | $4.08 | -41,226 | 158,580 | -21% | -$168,095 | |||||
| M | 2026-11-16 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $1.74 | +48,060 | 3,102,904 | +2% | +$83,435 | |||||
| M | 2026-11-16 | ANIP | Ani Pharmaceuticals Inc | Lalwani Nikhil | Pres, CEO | S - Sale | $71.22 | -5,400 | 328,289 | -2% | -$384,580 | |||||
| DM | 2026-11-16 | ANRO | Alto Neuroscience, Inc. | Hanley Jr. Michael Conick | COO | S - Sale+OE | $27.61 | -75,000 | 0 | -100% | -$2,070,389 | |||||
| D | 2026-11-16 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $53.53 | -7,500 | 282,710 | -3% | -$401,460 | |||||
2026-11-16 | SEPN | Septerna, Inc. | Labrucherie Gil M | CFO | S - Sale | $41.62 | -20,000 | 27,002 | -43% | -$832,359 | ||||||
2026-11-18 | BIVI | Biovie Inc. | Do Cuong V | Pres, CEO | P - Purchase | $1.00 | +2,500 | 21,117 | +13% | +$2,493 | ||||||
| D | 2026-11-17 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $51.78 | -3,500 | 153,902 | -2% | -$181,227 | |||||
| M | 2026-11-16 | ANAB | Anaptysbio, Inc | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $45.98 | +374,580 | 8,254,674 | +5% | +$17,224,593 | |||||
2026-11-17 | CYTK | Cytokinetics Inc | Hessekiel Jeffrey | Chief Legal, Admin Officer | S - Sale | $52.62 | -15,106 | 92,837 | -14% | -$794,878 | ||||||
| M | 2026-11-16 | ROIV | Roivant Sciences Ltd. | Manchester Keith S | Dir | S - Sale | $38.75 | -1,381,762 | 19,304,554 | -7% | -$53,536,738 | |||||
| M | 2026-11-16 | ROIV | Roivant Sciences Ltd. | Gold Daniel Allen | Dir | S - Sale | $38.75 | -1,381,762 | 19,304,554 | -7% | -$53,536,738 | |||||
2026-11-16 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale | $45.48 | -854 | 8,139 | -9% | -$38,840 | ||||||
| M | 2026-11-16 | ROIV | Roivant Sciences Ltd. | Qvt Financial LP | Director by Deputization | S - Sale | $38.75 | -1,381,762 | 19,304,554 | -7% | -$53,536,738 | |||||
2026-11-16 | CRMD | Cormedix Inc. | Kaplan Myron | Dir | P - Purchase | $4.88 | +25,000 | 286,487 | +10% | +$122,000 | ||||||
| D | 2026-11-16 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $61.88 | -2,812 | 105,272 | -3% | -$174,013 | |||||
| D | 2026-11-17 | RYTM | Rhythm Pharmaceuticals, Inc. | Jean Christophe | Dir | S - Sale+OE | $109.66 | -10,000 | 11,712 | -46% | -$1,096,550 | |||||
| D | 2026-11-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $580.43 | -9,500 | 668,728 | -1% | -$5,514,046 | |||||
| D | 2026-11-17 | ASND | Ascendis Pharma A/S | Pedersen Anni Lotte Kirstine Sonderbjerg | EVP, Chief Admin Officer | S - Sale+OE | $263.89 | -20,000 | 19,460 | -51% | -$5,277,720 | |||||
2026-11-16 | LRMR | Larimar Therapeutics, Inc. | Clayton Russell | Chief Medical Officer | P - Purchase | $3.01 | +3,322 | 74,765 | +5% | +$9,999 | ||||||
2026-11-16 | VRTX | Vertex Pharmaceuticals Inc / Ma | Thornberry Nancy | Dir | S - Sale | $547.86 | -1,000 | 1,109 | -47% | -$547,860 | ||||||
2026-11-16 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bhatia Sangeeta N. | Dir | S - Sale | $547.86 | -271 | 4,653 | -6% | -$148,470 | ||||||
2026-11-17 | RPRX | Royalty Pharma Plc | Hite Christopher | EVP, COB, Partnering | S - Sale | $68.15 | -100,000 | 200,723 | -33% | -$6,814,710 | ||||||
| M | 2026-11-16 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $68.81 | -257,122 | 50,390 | -84% | -$17,693,642 | |||||
2026-11-16 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $69.50 | -25,000 | 149,361 | -14% | -$1,737,490 | ||||||
| M | 2026-11-16 | REGN | Regeneron Pharmaceuticals, Inc. | Sing George L | Dir | S - Sale | $958.97 | -2,000 | 25,297 | -7% | -$1,917,945 | |||||
| D | 2026-11-16 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale+OE | $28.16 | -4,728 | 34,573 | -12% | -$133,140 | |||||
2026-11-16 | FLNA | Filana Therapeutics, Inc. | Barry Richard | Pres, CEO | P - Purchase | $0.47 | +440,206 | 1,778,170 | +33% | +$206,897 | ||||||
| D | 2026-11-16 | AMPH | Amphastar Pharmaceuticals, Inc. | Peters William J | CFO, EVP, Treasurer | S - Sale+OE | $29.99 | -11,000 | 167,076 | -6% | -$329,890 | |||||
2026-11-16 | FLNA | Filana Therapeutics, Inc. | Schoen Eric | CFO | P - Purchase | $0.42 | +20,000 | 31,500 | +174% | +$8,400 | ||||||
2026-11-16 | REGN | Regeneron Pharmaceuticals, Inc. | McCourt Marion | EVP Commercial | S - Sale | $960.26 | -566 | 10,524 | -5% | -$543,504 | ||||||
2026-11-18 | ALT | Altimmune, Inc. | Menziuso Richard Thomas | Principal Accounting Officer | P - Purchase | $1.42 | +10,000 | 10,000 | New | +$14,187 | ||||||
| D | 2026-11-17 | REGN | Regeneron Pharmaceuticals, Inc. | Murphy Andrew J | Co-Chief Scientific Officer | S - Sale+OE | $957.76 | -5,011 | 51,193 | -9% | -$4,799,336 | |||||
2026-11-16 | FLNA | Filana Therapeutics, Inc. | Cook Robert Christopher | COO,Legal Officer | P - Purchase | $0.46 | +121,575 | 135,300 | +886% | +$55,925 | ||||||
2026-11-16 | KURA | Kura Oncology, Inc. | Doyle Thomas James | SVP, Finance, Accounting | S - Sale | $7.44 | -4,697 | 138,581 | -3% | -$34,946 | ||||||
| M | 2026-11-16 | KURA | Kura Oncology, Inc. | Leoni Mollie | Chief Medical Officer | S - Sale | $7.45 | -41,250 | 99,845 | -29% | -$307,122 | |||||
| M | 2026-11-16 | KURA | Kura Oncology, Inc. | Powl Brian T. | Chief Commercial Officer | S - Sale | $7.45 | -24,450 | 113,265 | -18% | -$182,061 | |||||
2026-11-16 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | GC | S - Sale | $7.44 | -8,601 | 178,401 | -5% | -$63,991 | ||||||
| M | 2026-11-16 | KURA | Kura Oncology, Inc. | Ford Kathleen | COO | S - Sale | $7.45 | -10,710 | 132,276 | -7% | -$79,756 | |||||
2026-11-16 | IRWD | Ironwood Pharmaceuticals Inc | Gaskins Tammi L | Chief Commercial Officer | S - Sale | $4.81 | -5,919 | 344,431 | -2% | -$28,470 | ||||||
| D | 2026-11-18 | ZYME | Zymeworks Inc. | Platshon Scott | EVP, Chief Business Officer | S - Sale+OE | $24.95 | -15,292 | 21,745 | -41% | -$381,535 | |||||
2026-11-17 | CATX | Perspective Therapeutics, Inc. | Williamson Robert F III | Dir | P - Purchase | $0.84 | +25,000 | 168,744 | +17% | +$20,950 | ||||||
| M | 2026-11-16 | BOLT | Bolt Biotherapeutics, Inc. | Coastlands Capital LP | 10% | P - Purchase | $5.84 | +53,094 | 515,510 | +11% | +$309,922 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |